Cardlytics, Inc. (NASDAQ:CDLX) Given Average Rating of “Reduce” by Brokerages

Cardlytics, Inc. (NASDAQ:CDLX) has earned a consensus rating of “Reduce” from the six research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $7.50.

A number of equities analysts recently commented on CDLX shares. Needham & Company LLC cut shares of Cardlytics from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Craig Hallum downgraded Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Northland Capmk cut Cardlytics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 16th. Lake Street Capital lowered Cardlytics from a “buy” rating to a “hold” rating and reduced their target price for the stock from $18.00 to $5.00 in a research note on Thursday, August 8th. Finally, Northland Securities downgraded Cardlytics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $7.00 to $5.00 in a research report on Friday, August 16th.

Cardlytics Stock Down 2.8 %

Shares of NASDAQ CDLX opened at $3.11 on Friday. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 1.01. Cardlytics has a 12-month low of $2.89 and a 12-month high of $20.52. The firm’s 50-day moving average price is $4.68 and its 200-day moving average price is $8.67. The stock has a market capitalization of $151.72 million, a price-to-earnings ratio of -0.70 and a beta of 1.68.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. The firm had revenue of $69.64 million during the quarter, compared to analysts’ expectations of $75.39 million. During the same quarter in the previous year, the business earned ($0.57) EPS. The company’s quarterly revenue was down 9.2% on a year-over-year basis. On average, equities research analysts anticipate that Cardlytics will post -1.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Scott A. Hill bought 40,000 shares of the stock in a transaction on Monday, August 12th. The stock was acquired at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $143,200. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, COO Amit Gupta sold 22,699 shares of Cardlytics stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $8.66, for a total transaction of $196,573.34. Following the transaction, the chief operating officer now directly owns 150,569 shares of the company’s stock, valued at $1,303,927.54. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Scott A. Hill bought 40,000 shares of the stock in a transaction on Monday, August 12th. The shares were bought at an average price of $3.58 per share, with a total value of $143,200.00. Following the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $143,200. The disclosure for this purchase can be found here. 4.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its holdings in Cardlytics by 6.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after purchasing an additional 1,774 shares in the last quarter. Canton Hathaway LLC boosted its stake in Cardlytics by 95.7% in the second quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after acquiring an additional 2,200 shares in the last quarter. Susquehanna Fundamental Investments LLC grew its holdings in Cardlytics by 13.8% in the first quarter. Susquehanna Fundamental Investments LLC now owns 31,536 shares of the company’s stock worth $457,000 after purchasing an additional 3,836 shares during the last quarter. Quest Partners LLC increased its position in shares of Cardlytics by 160.4% during the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock worth $147,000 after purchasing an additional 11,061 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Cardlytics in the 2nd quarter worth $107,000. 68.10% of the stock is owned by institutional investors.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.